Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection

Abstract This study aimed to develop and validate a practical, reliable assay for prognosis and chemotherapy benefit prediction compared with conventional staging in Gastric cancer (GC). Twenty-three candidate genes with significant correlation between quantitative hybridization and microarray resul...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaohong Wang, Yiqiang Liu, Zhaojian Niu, Runjia Fu, Yongning Jia, Li Zhang, Duanfang Shao, Hong Du, Ying Hu, Xiaofang Xing, Xiaojing Cheng, Lin Li, Ting Guo, Ziyu Li, Qunsheng Ji, Lianhai Zhang, Jiafu Ji
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/fdaa7185fdb94e75a7e452352bb98925
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fdaa7185fdb94e75a7e452352bb98925
record_format	dspace
spelling	oai:doaj.org-article:fdaa7185fdb94e75a7e452352bb989252021-12-02T12:30:26ZPrognostic value of a 25-gene assay in patients with gastric cancer after curative resection10.1038/s41598-017-07604-y2045-2322https://doaj.org/article/fdaa7185fdb94e75a7e452352bb989252017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-07604-yhttps://doaj.org/toc/2045-2322Abstract This study aimed to develop and validate a practical, reliable assay for prognosis and chemotherapy benefit prediction compared with conventional staging in Gastric cancer (GC). Twenty-three candidate genes with significant correlation between quantitative hybridization and microarray results plus 2 reference genes were selected to form a 25-gene prognostic classifier, which can classify patients into 3 distinct groups of different risk of mortality obtained by analyzing microarray data from 78 frozen tumor specimens. The 25-gene assay was associated with overall survival in both training (P = 0.017) and testing cohort (P = 0.005) (462 formalin-fixed paraffin-embedded samples). The risk prediction in stages I + II is significantly better than that in stages III. Analysis demonstrated that this 25-gene signature is an independent prognostic predictor and show higher prognostic accuracy than conventional TNM staging in early stage patients. Moreover, only high-risk patients in stage I + II were found benefit from adjuvant chemotherapy (P = 0.043), while low-risk patients in stage III were not found benefit from adjuvant chemotherapy. In conclusion, our results suggest that this 25-gene assay can reliably identify patients with different risk for mortality after surgery, especially for stage I + II patients, and might be able to predict patients who benefit from chemotherapy.Xiaohong WangYiqiang LiuZhaojian NiuRunjia FuYongning JiaLi ZhangDuanfang ShaoHong DuYing HuXiaofang XingXiaojing ChengLin LiTing GuoZiyu LiQunsheng JiLianhai ZhangJiafu JiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Xiaohong Wang Yiqiang Liu Zhaojian Niu Runjia Fu Yongning Jia Li Zhang Duanfang Shao Hong Du Ying Hu Xiaofang Xing Xiaojing Cheng Lin Li Ting Guo Ziyu Li Qunsheng Ji Lianhai Zhang Jiafu Ji Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection
description	Abstract This study aimed to develop and validate a practical, reliable assay for prognosis and chemotherapy benefit prediction compared with conventional staging in Gastric cancer (GC). Twenty-three candidate genes with significant correlation between quantitative hybridization and microarray results plus 2 reference genes were selected to form a 25-gene prognostic classifier, which can classify patients into 3 distinct groups of different risk of mortality obtained by analyzing microarray data from 78 frozen tumor specimens. The 25-gene assay was associated with overall survival in both training (P = 0.017) and testing cohort (P = 0.005) (462 formalin-fixed paraffin-embedded samples). The risk prediction in stages I + II is significantly better than that in stages III. Analysis demonstrated that this 25-gene signature is an independent prognostic predictor and show higher prognostic accuracy than conventional TNM staging in early stage patients. Moreover, only high-risk patients in stage I + II were found benefit from adjuvant chemotherapy (P = 0.043), while low-risk patients in stage III were not found benefit from adjuvant chemotherapy. In conclusion, our results suggest that this 25-gene assay can reliably identify patients with different risk for mortality after surgery, especially for stage I + II patients, and might be able to predict patients who benefit from chemotherapy.
format	article
author	Xiaohong Wang Yiqiang Liu Zhaojian Niu Runjia Fu Yongning Jia Li Zhang Duanfang Shao Hong Du Ying Hu Xiaofang Xing Xiaojing Cheng Lin Li Ting Guo Ziyu Li Qunsheng Ji Lianhai Zhang Jiafu Ji
author_facet	Xiaohong Wang Yiqiang Liu Zhaojian Niu Runjia Fu Yongning Jia Li Zhang Duanfang Shao Hong Du Ying Hu Xiaofang Xing Xiaojing Cheng Lin Li Ting Guo Ziyu Li Qunsheng Ji Lianhai Zhang Jiafu Ji
author_sort	Xiaohong Wang
title	Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection
title_short	Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection
title_full	Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection
title_fullStr	Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection
title_full_unstemmed	Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection
title_sort	prognostic value of a 25-gene assay in patients with gastric cancer after curative resection
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/fdaa7185fdb94e75a7e452352bb98925
work_keys_str_mv	AT xiaohongwang prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT yiqiangliu prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT zhaojianniu prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT runjiafu prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT yongningjia prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT lizhang prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT duanfangshao prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT hongdu prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT yinghu prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT xiaofangxing prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT xiaojingcheng prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT linli prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT tingguo prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT ziyuli prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT qunshengji prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT lianhaizhang prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection AT jiafuji prognosticvalueofa25geneassayinpatientswithgastriccanceraftercurativeresection
_version_	1718394374991118336

Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection

Ejemplares similares